Determining variation in glucose levels in people with impaired glucose tolerance (prediabetes)

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
03/05/2019		☐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
22/05/2019		[X] Results		
Last Edited 10/06/2024	Condition category Nutritional, Metabolic, Endocrine	[] Individual participant data		
10/00/2024	NULLILIONAL MELADOUC, ENGOCIME			

Plain English summary of protocol

Background & study aims

The number of people with diabetes continues to rise throughout the world. In addition, there has been a similar rise in impaired glucose tolerance or prediabetes, which is a risk factor for developing type 2 diabetes. The aim of this pilot study is to collect glucose data using the FreeStyle Libre Pro Flash Glucose Monitoring System from adults with impaired glucose tolerance.

Who can participate?

Patients aged 18 and over with an HbA1c of 5.7-6.4% (39-47 mmol/mol).

What does the study involve?

Participants will wear two FreeStyle Libre Pro Sensors for up to 14 days (glucose data is not visible during this time). Participants will also be supplied with a fitness tracker and a tablet; an app will be pre-installed on the tablet and participants will be requested to record dietary intake for three days.

Participants will return to clinic for Sensor removal and data upload (Sensor and tracker), they will then wear a FreeStyle Libre Sensor for up to 14 days (glucose data will be visible during this time). Participants will be requested to complete a questionnaire at the end of the study.

What are the possible benefits & risks of participating?

The study gives participants with impaired glucose tolerance the opportunity to experience sensor technology using the FreeStyle Libre Pro and FreeStyle Libre Systems. The only risks associated with the study are from obtaining venous blood samples, these are small but could include pain, bruising, local infection and fainting. Data collected may be used to inform future pivotal clinical study designs in this population.

Where is the study run from?

- 1. Hathaway Medical Centre, Chippenham
- 2. Claremont Medial Practice, Exmouth
- 3. Albany House Medical Centre, Wellingborough

- 4. The Adam Practice, Hamworthy
- 5. Atherstone Surgery, Atherstone

When is the study starting and how long is it expected to run for? 28/05/2019 to 31/07/2019

Who is funding the study? The study is funded by Abbott Diabetes Care Ltd

Who is the main contact? Dr Pamela Reid

Contact information

Type(s)

Public

Contact name

Dr Pamela Reid

Contact details

Abbott Diabetes Care Range Road Witney United Kingdom OX29 0YL +44 1993 863024 Pamela.Reid@abbott.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

ADC-UK-PMS-19041

Study information

Scientific Title

A pilot study to determine glycaemic variability in people with impaired glucose tolerance (prediabetes)

Acronym

SAGE

Study objectives

This pilot study is being conducted to determine the amount of glycaemic variability (measured by %CV glucose) in people with impaired glucose tolerance (prediabetes).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 17/05/2019, NRES Committee: South West – Cornwall and Plymouth Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT; +44 (0)207 104 8048; nrescommittee.southwest-cornwall-plymouth@nhs.net), ref: 19/SW/0087

Study design

Prospective multi-centre single-arm pilot study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Impaired glucose tolerance

Interventions

Participants will wear two FreeStyle Libre Pro Flash Glucose Monitoring Sensors for up to 14 days, followed by FreeStyle Libre for up to 14 days. During the Libre Pro sensor wear, participants will wear a fitness tracker (throughout the two weeks) and record dietary intake (for three days).

There is no follow-up period unless the participant experiences an unanticipated adverse device effect (ADE).

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

FreeStyle Libre Pro Flash Glucose Monitoring Sensor, FreeStyle Libre

Primary outcome(s)

Glycaemic variability (%CV glucose), measured using sensor glucose data collected by the FreeStyle Libre Pro Flash Glucose Monitoring System during the first two-weeks of the study.

Key secondary outcome(s))

Other glycaemic measures such as time in range (3.9-10.0 mmol/L [70-180 mg/dL]), measured using sensor glucose data collected by the FreeStyle Libre Pro Flash Glucose Monitoring System during the first two-weeks of the study.

Completion date

Eligibility

Key inclusion criteria

- 1. Aged 18 years or over.
- 2. Most recent HbA1c 5.7-6.4% (39-47 mmol/mol), recorded in medical notes in last 12 months.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

43

Key exclusion criteria

- 1. Recorded diagnosis of diabetes.
- 2. Concomitant disease or condition that may compromise patient safety including and not limited to; cystic fibrosis, severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition.
- 3. Has a pacemaker or any other neurostimulators.
- 4. Currently receiving dialysis treatment or planning to receive dialysis during the study.
- 5. Women who are pregnant, plan to become pregnant or become pregnant during the study.
- 6. Participating in another study of a glucose monitoring device or drug that could affect glucose measurements or management.
- 7. Known (or suspected) allergy to medical grade adhesives.
- 8. In the investigator's opinion, unsuitable to participate due to any other cause/reason.

Date of first enrolment

28/05/2019

Date of final enrolment

27/07/2019

Locations

Countries of recruitment

United Kingdom

England

Study participating centre Hathaway Medical Centre United Kingdom SN14 6GT

Study participating centre Claremont Medial Practice United Kingdom EX8 2JF

Study participating centre
Albany House Medical Centre
United Kingdom
NN8 4RW

Study participating centre The Adam Practice United Kingdom BH15 4JQ

Study participating centre Atherstone Surgery United Kingdom CV9 1EU

Sponsor information

Organisation

Abbott Diabetes Care Ltd

ROR

https://ror.org/03wnay029

Funder(s)

Funder type

Industry

Funder Name

Abbott Diabetes Care

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Pamela Reid.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

2 2 2 3 7 2 3 P 2 3 2					
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results		01/06/2020	01/07/2022	Yes	No
Abstract results		25/08/2020	10/06/2024	No	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes